United Therapeutics CEO trust sells 9,500 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
United Therapeutics (UTHR) reported that a family trust in which Chairperson & CEO Martine A. Rothblatt shared investment power exercised 9,500 stock options on November 13, 2026, at an exercise price of $117.76 per share, acquiring 9,500 common shares. The trust sold 9,500 shares that day at reported prices ranging from $587.4172 to $598.8300 per share. The exercise and sales were under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported post-exercise position was 24,410 stock options.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F17, F18 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $117.76 | $1.12M |
| Sale | Common Stock F1, F3, F2 | 528 | $587.4172 | $310K |
| Sale | Common Stock F1, F4, F2 | 493 | $588.6066 | $290K |
| Sale | Common Stock F1, F5, F2 | 603 | $589.7952 | $356K |
| Sale | Common Stock F1, F6, F2 | 1,657 | $590.6467 | $979K |
| Sale | Common Stock F1, F7, F2 | 2,181 | $591.5625 | $1.29M |
| Sale | Common Stock F1, F8, F2 | 518 | $592.6125 | $307K |
| Sale | Common Stock F1, F9, F2 | 245 | $593.8078 | $145K |
| Sale | Common Stock F1, F10, F2 | 1,275 | $594.654 | $758K |
| Sale | Common Stock F1, F11, F2 | 1,040 | $595.4145 | $619K |
| Sale | Common Stock F1, F12, F2 | 480 | $596.6476 | $286K |
| Sale | Common Stock F1, F13, F2 | 440 | $597.4796 | $263K |
| Sale | Common Stock F1, F2 | 40 | $598.83 | $24K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock F14 | -- | -- | -- |
| Holding | Common Stock F15 | -- | -- | -- |
| Holding | Common Stock F16 | -- | -- | -- |
Footnotes (18)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $594.15 to $595.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $595.17 to $596.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $596.18 to $597.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $597.25 to $598.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F15. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F16. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F17. These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
- F18. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $587.01 to $588.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $588.09 to $589.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $589.12 to $590.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $590.12 to $591.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $591.12 to $592.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $592.13 to $593.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $593.15 to $594.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
pre-arranged 10b5-1 trading plan regulatory
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of the UTHR Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.